Vaporized DMT produced fast and lasting improvements in depression symptoms and suicidal ideation, according to a new phase 2a trial, highlighting its potential as a scalable, non-invasive alternative to conventional and long-acting psychedelic treatments for severe depression.
New findings reveal that 5-MeO-DMT, a fast-acting psychedelic, can change brain gene activity and reduce anxiety-related behavior in stressed mice, offering promising insights into its lasting effects and potential use in treating anxiety disorders.
New research reveals that serotonin in the gut lining can reduce anxiety and depression symptoms in mice—without the side effects of traditional antidepressants—and may offer a safer alternative for treating mood disorders during pregnancy.
New research suggests that hormones linked to the body’s stress response do not influence how people with treatment-resistant depression respond to ketamine. However, lower hormone levels were associated with longer depressive episodes, pointing to possible biomarkers for depression duration.
French researchers surveyed hundreds of psychedelic users and found that mystical experiences predicted lasting improvements in psychological flexibility. These findings shed light on how psychedelics might promote emotional resilience by disrupting rigid thinking patterns and encouraging openness to experience.
A new study used fMRI and EEG to show that DMT reduces the energy needed for the brain to shift between activity states. These changes tracked with increased signal complexity and were strongest in regions rich in serotonin 2a receptors.
A new study published in the Journal of Psychiatric Research finds that alcohol harms quality of life more severely in individuals with ADHD. Emotional dysregulation and impulsivity appear to intensify the negative effects of alcohol in this vulnerable group.
Psychedelics are often described as spiritual tools—but do they change people’s religious beliefs? A large new study found that while psychedelic use was associated with religious disaffiliation, it did not cause lasting changes in religiosity or spirituality over time.
In a rodent model of childhood adversity, escitalopram treatment during adolescence reduced signs of emotional distress. The study also found gene-level changes in the endocannabinoid system, pointing to a possible biological mechanism for the drug’s effectiveness.
A new open-label study suggests that a single dose of psilocybin, combined with psychological support, may reduce symptoms in people with severe treatment-resistant depression. Improvements were sustained for up to 12 weeks, although effects were weaker in those with PTSD.
Cannabidiol appears to improve social memory in mice, according to new research in Psychopharmacology. The study shows that CBD enhances the ability to remember food-related information from peers by increasing acetylcholine activity in the basal forebrain.
A new animal study shows that adolescent use of fluoxetine, a commonly prescribed antidepressant, may have long-lasting effects on how the brain processes pain. Female mice exposed to the drug displayed increased sensitivity to heat stimuli as adults.
Psilocybin use has surged across the U.S. in recent years, with the biggest increases seen among adults with depression, anxiety, and chronic pain.
Researchers investigating the psychedelic drug DOPR discovered that very low doses can enhance motivation in low-performing mice—without triggering behaviors linked to hallucinations. The findings point to the therapeutic potential of psychedelics at doses too low to alter perception.
Researchers in Switzerland have completed the first randomized trial comparing legal and illegal cannabis use. The study suggests that public health-oriented cannabis access may help reduce misuse, particularly among people with more complex patterns of drug use.